My Treatment Approach: Optimal Second- and Third-Line Treatment Options of cGVHD | Supplements And Featured Publications

The My Treatment Approach: Optimal Second- and Third-Line Treatment Options of cGVHD publication covers some of the latest and practice-changing advances in the treatment for patients with chronic graft-vs-host disease following recent regulatory decisions and data read outs from pivotal clinical trials, as well as expert insights on how they approach therapy on an individualized basis.


Preventive and Early Intervention Strategies Among Next Steps in cGVHD Management

October 28, 2021

As the armamentarium continues expanding for the treatment of patients with chronic graft-vs-host disease, research is ongoing to determine whether earlier integration of novel therapies, such as ruxolitinib, could yield better response rates for patients.

cGVHD Paradigm Gains Systemic Options Beyond Steroids, But Real-World Data Are Required

October 27, 2021

Yi-Bin Chen, MD, discusses the nuances of diagnosing patients with cGVHD, the need for biomarkers to inform who is likely to develop the disease, the introduction of ruxolitinib and belumosudil to the paradigm, and future directions with novel strategies in the space.